Solutions We Offer

Chemistry solutions and process R&D

Contact Us
Solutions We Offer

News

SynZeal is expanding its synthetic expertise to cover synthesis of synthetic and semi-synthetic peptide from gram to Kg scale. SynZeal provides a versatile platform catering to several application for pharmaceutical companies at various platforms. Our highly experienced team with extensive know-how in sequence design and modifications will deliver every peptide with the desired quality. Know more about SynZeal Peptide and its availability.

about-img

About SynZeal

SynZeal specializes in the development of pharmacopeial and non-pharmacopeial pharmaceutical reference standards, drug metabolites, glucuronides, nitrosamines, and stable isotope-labelled compounds. Driven by an unwavering commitment to quality, we deliver products that meet the highest industry standards. Our expertise lies in the custom synthesis of complex organic molecules—a core focus that shapes everything we do. With an extensive inventory covering a wide range of products, With a broad and growing inventory, SynZeal is a trusted research partner for drug development, analytical validation, and quality-controlled applications. We are constantly evolving our offerings to stay ahead of evolving stringent global regulatory demands.

Latest Events

SynZeal visited CPhI Japan, premier pharmaceutical exhibition, widely seen as a barometer of overall health in the country’s pharma industry from Apr 9-11, 2025 at the Tokyo. It was opportunity to know current trends, development and challenges of Japan Pharm industry.

event-img
medicine-image

Fluocinonide

Date: Thursday, April 1, 2025 /

Fluocinonide is a synthetic glucocorticoid receptor initiated by transcription of the ligand-receptor complex to the nucleus and transcriptional activation of genes containing glucocorticoid responsive elements. Fluocinonide has been used in trials studying the treatment and prevention of Candida Infection, Oral Lichen Planus, Macular Degeneration, and Candida Keratitis/Endophthalmitis. It was patented in 1964 and approved for medical use in 1971.

Accreditation

We are committed to excellence in pharmaceutical research, proudly holding accreditations that ensure the highest standards of quality and ethics in our work. These certifications reflect our dedication to reliable and impactful outcomes.

Looking for specific products not listed on our website? SynZeal has extensively experience in developing product of your interest. We help you accelerate your research projects. Talk to our team of experts to know how?

SCHEDULE MEETING